Although it has been announced that Mounjaro (Tirzepatide) will become available in primary care settings from Monday, 23 June (for a specific patient cohort) arrangements are being made by Kent and Medway ICB to mobilise a provider of the necessary Behavioural Support for Obesity Prescribing (BSOP) that is specified in the NICE guidelines. Until this service is in place in Kent and Medway, it is not possible to prescribe Mounjaro (Tirzepatide) in primary care. This means your GP Practice is unable to prescribe these medicines solely for weight loss at this time.
Once the service becomes available to be prescribed, the first cohort of patients must have a BMI (Body Mass Index) of 40 plus and four or more of the following diagnosed health conditions:-
Type 2 Diabetes
High Blood Pressure
Heart Disease
Obstructive Sleep Apnoea
Abnormal Blood Fats (Dyslipidaemia)
Follow this link to view the full update from the Kent and Medway ICB